Loading...
XNASLGND
Market cap2.01bUSD
Jan 10, Last price  
106.28USD
1D
-3.89%
1Q
3.24%
Jan 2017
4.60%
Name

Ligand Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:LGND chart
P/E
38.51
P/S
15.29
EPS
2.76
Div Yield, %
0.00%
Shrs. gr., 5y
-5.90%
Rev. gr., 5y
-12.18%
Revenues
131m
-33.09%
163,512,000176,608,000140,960,00012,894,00027,315,00038,940,00023,538,00030,037,00031,388,00048,974,00064,538,00071,914,000108,973,000141,102,000251,453,000120,282,000186,419,000277,133,000196,245,000131,314,000
Net income
52m
P
-45,141,000-36,399,000-31,743,000281,688,000-98,114,000-1,948,000-12,515,00010,176,000-527,00011,421,00012,024,000257,305,000-1,636,00012,556,000143,321,000629,302,000-2,985,00057,138,000-5,219,00052,154,000
CFO
50m
-64.04%
5,754,0008,365,000-138,521,000-97,727,000-20,625,000-33,801,000-27,067,000-1,172,000161,00020,690,00020,566,00041,727,00063,001,00093,568,000194,059,000-29,336,00054,586,00078,798,000137,850,00049,577,000
Dividend
Jul 02, 20100.1218 USD/sh
Earnings
Feb 25, 2025

Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
URL
https://www.ligand.com/
IPO date
Nov 18, 1992
Employees
76
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
131,314
-33.09%
196,245
-29.19%
Cost of revenue
112,376
158,971
Unusual Expense (Income)
NOPBT
18,938
37,274
NOPBT Margin
14.42%
18.99%
Operating Taxes
9,841
41,230
Tax Rate
51.96%
110.61%
NOPAT
9,097
(3,956)
Net income
52,154
-1,099.31%
(5,219)
-109.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
17,901
(5,004)
BB yield
-1.41%
0.44%
Debt
Debt current
410
77,410
Long-term debt
11,920
21,387
Deferred revenue
1,444
30,615
Other long-term liabilities
62,322
(5,193)
Net debt
(206,300)
(116,073)
Cash flow
Cash from operating activities
49,577
137,850
CAPEX
(3,521)
(17,923)
Cash from investing activities
(11,682)
163,624
Cash from financing activities
(59,947)
(275,990)
FCF
(21,373)
65,477
Balance
Cash
170,309
211,870
Long term investments
48,321
3,000
Excess cash
212,064
205,058
Stockholders' equity
502,217
450
Invested Capital
558,780
710,203
ROIC
1.43%
ROCE
2.46%
5.03%
EV
Common stock shares outstanding
17,757
16,868
Price
71.42
6.92%
66.80
-56.75%
Market cap
1,268,205
12.55%
1,126,782
-57.70%
EV
1,061,905
1,010,709
EBITDA
54,581
88,644
EV/EBITDA
19.46
11.40
Interest
656
1,799
Interest/NOPBT
3.46%
4.83%